AstraZeneca’s Tozorakimab Shows Strong Phase III Results in COPD

AstraZeneca’s Tozorakimab Shows Strong Phase III Results in COPD

By, Admin 30 March 2026

AstraZeneca has reported positive Phase III results for its investigational biologic tozorakimab, offering new hope for patients with Chronic Obstructive Pulmonary Disease (COPD).

Data from the OBERON and TITANIA trials show that the drug significantly reduced moderate-to-severe COPD exacerbations, a key driver of hospitalizations and mortality.

Key Trial Results: What Stood Out

The Phase III trials evaluated tozorakimab in patients already receiving standard inhaled therapy but still experiencing exacerbations.

Primary Outcomes

  • Reduced annualised exacerbation rate vs placebo
  • Benefit seen in:
    • Former smokers (primary population)
    • Overall population (including current smokers)
  • Effective across:
    • All blood eosinophil levels
    • All stages of lung function severity

Safety Profile

  • Generally well tolerated
  • Favourable safety profile reported

Why Tozorakimab Is Different?

Tozorakimab is a first-in-class monoclonal antibody targeting interleukin-33 (IL-33), a key driver of inflammation in COPD.

Mechanism of Action

Unlike traditional biologics, it:

  • Blocks both reduced and oxidised IL-33 forms
  • Targets the top of the inflammatory cascade
  • Helps:
    • Reduce airway inflammation
    • Disrupt mucus dysfunction cycles

This dual-action approach could address multiple disease drivers simultaneously.

Trial Design: OBERON & TITANIA at a Glance

  • Total patients: 2,306
  • Duration: 52 weeks
  • Dosing: 300 mg every 4 weeks
  • Background therapy: Standard inhaled treatment

Patient Criteria

  • Symptomatic COPD
  • ≥2 moderate OR ≥1 severe exacerbation in past year
  • Included:
    • Former & current smokers
    • All eosinophil levels
    • All disease severities

The Bigger Problem: COPD Is Still Largely Uncontrolled

COPD remains one of the toughest respiratory diseases to manage.

Global Burden

  • ~400 million patients worldwide
  • 3rd leading cause of death globally
  • 50% of patients still experience exacerbations despite treatment

Why Exacerbations Matter

  • Increase risk of:
    • Hospitalisation
    • Cardiopulmonary events
    • Death
  • Accelerate disease progression

In the U.S. alone:

  • 2,500 emergency visits per day due to exacerbations
  • Only 50% of patients survive beyond 3.5 years after a severe episode

Expert Take: A Potential Shift in COPD Treatment

Clinical experts emphasized the significance of targeting IL-33.

  • The trials showed consistent benefit across diverse patient groups
  • This is critical in COPD, a disease known for its heterogeneity
  • Results suggest a broadly applicable biologic therapy, not limited to niche subgroups

What’s Next: More Trials in Progress?

Tozorakimab’s development program is far from over.

Ongoing Phase III Trials

  • PROSPERO
    • Long-term extension study
    • Focus: Severe exacerbations over 104 weeks
    • Results expected: H1 2026
  • MIRANDA
    • Evaluating dosing every 2 weeks
    • Broader population inclusion
    • Results expected: H1 2026

Beyond COPD

Tozorakimab is also being studied in:

  • Severe viral lower respiratory tract disease (Phase III)
  • Asthma (Phase II)

Regulatory Momentum

The therapy has already received Fast Track Designation from the U.S. Food and Drug Administration for:

  • Severe viral respiratory disease (2023)
  • COPD (2024)

This could accelerate its path to approval if results continue to hold.

Final Take

Tozorakimab is shaping up to be more than just another COPD drug.

It represents:

  • A new biological pathway (IL-33)
  • A broad-spectrum approach across patient types
  • A potential tool to finally reduce persistent exacerbations

If upcoming trials confirm these findings, AstraZeneca could redefine how COPD is treated—moving closer to controlling a disease that has remained stubbornly resistant to innovation.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!